TrialJournal of immunology (Baltimore, Md. : 1950)2017

Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10.

Alexandra Zanin-Zhorov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.